200400-76-6 Usage
General Description
Ethyl 2-(4'-hydroxyphenyl)-1,3-oxazole-4-carboxylate is a complex chemical compound falls under the category of Oxazole Derivates. Its molecular formula is C13H11NO4, and it has a molecular weight of 249.23 g/mol. It is characterized by the presence of a hydroxyphenyl group and an oxazole ring. Oxazoles are aromatic compounds that possess a five-member ring with two heteroatoms, one oxygen and one nitrogen atom, which are in the 1,3-position. Ethyl 2-(4'-hydroxyphenyl)-1,3-oxazole-4-carboxylate and other oxazoles have significant potential in medicinal chemistry as they exhibit a wide range of biological activities. However, there’s no significant data available specifically about this compound.
Check Digit Verification of cas no
The CAS Registry Mumber 200400-76-6 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,0,0,4,0 and 0 respectively; the second part has 2 digits, 7 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 200400-76:
(8*2)+(7*0)+(6*0)+(5*4)+(4*0)+(3*0)+(2*7)+(1*6)=56
56 % 10 = 6
So 200400-76-6 is a valid CAS Registry Number.
200400-76-6Relevant articles and documents
Design, synthesis and biological evaluation of 2,4-disubstituted oxazole derivatives as potential PDE4 inhibitors
Li, Ya-Sheng,Hu, De-Kun,Zhao, Dong-Sheng,Liu, Xing-Yu,Jin, Hong-Wei,Song, Gao-Peng,Cui, Zi-Ning,Zhang, Lian-Hui
, p. 1852 - 1859 (2017/03/08)
In this study, a series of pyrazole derivatives containing 4-phenyl-2-oxazole moiety were designed and synthesized in a concise way, some of which exhibited considerable inhibitory activity against PDE4B and blockade of LPS-induced TNF-α release. Compound
PREPARATION OF SUBSTITUTED ALKENOIC ACIDS
-
, (2008/06/13)
This invention relates to a highly selective process for preparation of E-ω-phenyl-ω-(3-pyridyl)-ω-alkenoic acid derivatives bearing a carbamoyl substituted oxazolyl or oxazolinyl group on the phenyl ring which demonstrate utility for thromboxane receptor antagonism and/or thromboxane synthase inhibition, as well as to intermediates therefor.
